You can negotiate with health plans
November 1st 2008Depending on your location, your specialty, and the size of your practice, insurers may actually want to keep you happy, especially if you threaten to walk away from a bad deal. If nothing else, negotiations may reveal that lowball reimbursement for a particular code is nothing more than an inadvertent mistake that most insurers are willing to correct.
How to collect past-due payments from patients without scaring them away
November 1st 2008Physician groups are adopting tougher collection tactics, largely in response to tough times. What compounds their problem of skimpy third-party reimbursements and rising overhead is having to depend on patients for a bigger portion of their revenue stream-a result of the rising number of uninsured and the growth of high-deductible health plans.
Evaluating your competition: industry and non-industry
November 1st 2008Losing even one patient to another local practice is one too many. To achieve and maintain an edge in the LASIK market, you've got to stay on top of your competitors with research and analysis, and regularly evaluate where you fit in terms of image and consumer perception.
New spectral-domain optical coherence tomography algorithms can provide objective retina exam
November 1st 2008Use of spectral-domain optical coherence tomography with automated image processing seems to provide more objective and potentially more reproducible assessments of the optic nerve head when compared with ophthalmologists' assessments of conventional fundus photos.
ISTA Pharmaceuticals reaches funding agreement
November 1st 2008ISTA Pharmaceuticals, Inc. has entered into an agreement with Deerfield Management, Sprout, and Sanderling Ventures, three of its long-term shareholders, to provide it with up to $65 million in financing through a flexible credit facility.
Intracameral triamcinolone may be viable PKP treatment
November 1st 2008Topical, periocular, and/or systemic corticosteroids typically are used to treat corneal endothelial graft rejection. When those modalities fail, experience in a series of five eyes suggests intracameral triamcinolone acetonide may be worth considering.
Take a new look at existing devices, surgeon suggests
November 1st 2008The high-tech devices available today are changing the way ophthalmology is practiced. According to the surgeon, the new technology found in state-of-the-art optical coherence tomography goes much further than assisting ophthalmologists in the diagnostics of anterior eye and retinal disorders.
Fixed-combination therapies offer option for greater pressure reduction
November 1st 2008Monotherapy is usually the first step in glaucoma therapy, but when IOP is not sufficiently lowered with a single agent, a fixed combination can be considered. The advantages, limitations, and features of fixed combinations of IOP-lowering agents available worldwide are reviewed.
Acucela, Otsuka enter into agreements
November 1st 2008Acucela Inc. and Otsuka Pharmaceutical Co. Ltd. have entered into agreements to co-develop Otsuka's proprietary compound for the treatment of dry eye (Rebamipide), which is in phase III clinical trials in the United States, as well as Acucela's lead compound (ACU-4429), which is in phase I clinical trials for non-exudative (dry) age-related macular degeneration in the United States.
The International Society of Bilateral Cataract Surgery holds inaugural meeting during ESCRS
November 1st 2008The inaugural meeting of the International Society of Bilateral Cataract Surgeons (ISBCS) was held Sept. 1, during the recent annual meeting of the European Society of Cataract and Refractive Surgeons (ESCRS).
Sun, anti-oxidant may predict age-related macular degeneration risk
November 1st 2008A combination of blue light exposure and low blood levels of anti-oxidants may be associated with an increased risk of neovascular age-related macular degeneration (AMD), as well as early AMD, according to research published in the October issue of Archives of Ophthalmology.
HIV drugs needed globally to control disease long term
November 1st 2008Human immunodeficiency virus (HIV) has become a manageable chronic disease, but that is true only in rich countries that have a relatively small number of HIV cases. With the evolution of treatment, patients can expect a natural life expectancy with the available therapies. These treatments are needed globally in third-world countries where most of the cases are.